Skip banner and top navigation
NHLBI Logo and Link
National Heart, Lung, and Blood Institute: People, Science, Health
 HOME  SITE INDEX  CONTACT US
  
  Patient Recruitment - Multiple Myeloma
TIPS     ADVANCED SEARCH
 

Research Studies        
Escalating Doses of ON 01910.Na for Multiple Myeloma   Stem Cell Transplant to Treat Multiple Myeloma

Multiple Myeloma Research Study

Escalating Doses of ON 01910.Na for Multiple Myeloma

Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for Multiple Myeloma (MM). The study drug, ON01910.Na is classified as mitotic inhibitor and works by interrupting the life cycle of myeloma cells. Consenting subjects will receive 2 days of drug infusion once every other week (1 cycle) for a minimum of 2 cycles. Subjects without toxicity will have the option to continue the regimen for 2 additional cycles, after which if there is evidence of response, subjects may continue the regimen indefinitely.

If you are between the ages of 18 and 99 and have been diagnosed with MM and have failed to respond to, relapsed following, are not eligible for, or opted not to participate in other standard of care treatment options you may be able to participate in a clinical trial. This study will determine what dose and which dosing schedule of this new drug is safe. We will also evaluate whether or not this drug can slow progression of your illness, improve blood counts, and/or reduce the need for transfusions of blood and/or platelets.

To find out if you qualify, please call our study coordinator at 301-402-0797 or email us at BloodStudy@nhlbi.nih.gov
 
Email This Study To A Friend       View/Print PDF Version Of This Study

Protocol Information

Disease and Treatment Information

Support Groups
 

 

Multiple Myeloma Research Study

Stem Cell Transplant to Treat Multiple Myeloma

If you (or someone you know) have been diagnosed with Multiple Myeloma or Waldenstrom's macroglobulinemia, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether special treatment of donor stem cells and delaying the transfusion of donor immune cells will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister who is willing to participate as a donor in order to participate in this study.

To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov

 
Email This Study To A Friend       View/Print PDF Version Of This Study

Protocol Information

Disease and Treatment Information

Support Groups
 

 
 
Spacer

NHLBI HOME · ACCESSIBILITY INFORMATION · NHLBI AT THE CLINICAL CENTER · PRIVACY STATEMENT · SUPPORTED BROWSERS · WEB TECHNICAL CONTACT· v1.2.0.1